Anti‐CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti‐CCP2 antibodies in Egyptian patients with rheumatoid arthritis

References

• Rasker J. J., Cosh J. A. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis 1981; 40: 115–20
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E. Rheumatoid arthritis: more aggressive approach improves outlook. Cleve Clin J Med 2004; 71: 409–13
   PubMedGoogle Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Saraux A., Berthelot J. M., Chales G., Le Henaff C., Mary J. Y., Thorel J. B., et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002; 47: 155–65
   PubMedGoogle Scholar
• Bas S., Perneger T. V., Kunzle E., Vischer T. L. Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis 2002; 61: 505–10
   PubMed Web of Science ®Google Scholar
• Rantapaa‐Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005; 34: 83–96
   PubMed Web of Science ®Google Scholar
• Bartfeld H. Incidence and significance of seropositive tests for rheumatoid factor in non‐rheumatoid disease. Ann Intern Med 1960; 52: 1059–66
   Web of Science ®Google Scholar
• Shmerling R. H., Delbanco T. L. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991; 91: 528–34
   PubMed Web of Science ®Google Scholar
• Van Boekel M. A. M., Vossenaar E. R., Van den Hoogen F. H. J., Van Venrooij W. J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87–93
   PubMedGoogle Scholar
• Nikolaisen C., Rekvig O. P., Nossent H. C. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis. Scand J Rheumatol 2007; 36: 97–100
   PubMed Web of Science ®Google Scholar
• Schellekens G. A., de Jong B. A., van den Hoogen F. H., van de Putte L. B., van Venrooij W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis‐specific autoantibodies. J Clin Invest 1998; 101: 273–81
   PubMed Web of Science ®Google Scholar
• van Venrooji W. J., Hazes J. M., Visser H. Anti‐citrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002; 60: 383–8
   PubMedGoogle Scholar
• Zendman A. J., Vossenaar E. R., van Venrooji W. J. Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004; 37: 295–9
   PubMed Web of Science ®Google Scholar
• Schellekens G. A., Visser H., de Jong B. A., van den Hoogen F. H., Hazes J. M., Breedveld F. C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–63
   PubMed Web of Science ®Google Scholar
• Kroot E. J., de Jong B. A., van Leeuwen M. A., Swinkels H., van den Hoogen F. H., van't Hof M., et al. The prognostic value of anti‐cyclic citrullinated peptide antibody in patients with recent‐onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831–5
   PubMed Web of Science ®Google Scholar
• van Gaalen F. A., Visser H., Huizinga T. W. J. A comparison of the diagnostic accuracy and prognostic value of the first and second anti‐cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1510–12
   PubMed Web of Science ®Google Scholar
• Kwok J. S., Hui K. H., Lee T. L., Wong W., Lau Y. L., Wong R. W., et al. Anti‐cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005; 34: 359–66
   PubMed Web of Science ®Google Scholar
• Prevoo M. L. L., van't Hof M. A., Kuper H. H., et al. Modified disease activity scores that include twenty‐eight‐joint counts. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Ferraz M. B., Quaresma M. R., Aquino L. R., Atra E., Tugwell P., Goldsmith C. H. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1022–4
   PubMed Web of Science ®Google Scholar
• Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• van der Heijde D., Dankert T., Nieman F., Rau R., Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 941–7
   PubMed Web of Science ®Google Scholar
• Riedemann J. P., Munoz S., Kavanaugh A. The use of second generation anti‐CCP antibody (anti‐CCP2) testing in rheumatoid arthritis: a systematic review. Clin Exp Rheumatol 2005; 23((Suppl 39))S69–76
   Google Scholar
• O'Dell J. R. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis Rheum 2002; 46: 283–5
   PubMed Web of Science ®Google Scholar
• Alexiou I., Germenis A., Ziogas A., Theodoridou K., Sakkas L. I. Diagnostic value of anti‐cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 2007; 8: 37
   PubMed Web of Science ®Google Scholar
• Bombardieri M., Alessandri C., Labbadia G., Iannuccelli C., Carlucci F., Riccieri V., et al. Role of anti‐cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection‐associated polyarticular involvement. Arthritis Res 2004; 6: R137–41
   Google Scholar
• Choi S. W., Lim M. K., Shin D. H., Park J. J., Shim S. C. Diagnostic performances of anti‐cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci 2005; 20: 473–8
   PubMedGoogle Scholar
• xCorrea P. A., Tobón G. J., Citera G., Cadena J., Schneeberger E., Camargo J. F., et al. [Anti‐cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA‐DRB1], in Spanish. Biomedica 2004; 24: 140–52
   PubMedGoogle Scholar
• De Rycke L., Peene I., Hoffman I. E., Kruithof E., Union A., Meheus L., et al. Rheumatoid factor and anti‐citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra‐articular manifestations. Ann Rheum Dis 2004; 63: 1587–93
   PubMed Web of Science ®Google Scholar
• Dubucquoi S., Solau‐Gervais E., Lefranc D., Marguerie L., Sibilia J., Goetz J., et al. Evaluation of anti‐citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004; 63: 415–19
   PubMed Web of Science ®Google Scholar
• Grootenboer‐Mignot S., Nicaise‐Roland P., Delaunay C., Meyer O., Chollet‐Martin S., Labarre C. Second generation anti‐cyclic citrullinated peptide (anti‐CCP2) antibodies can replace other filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol 2004; 33: 218–20
   PubMed Web of Science ®Google Scholar
• Lee D. M., Schur P. H. Clinical utility of the anti‐CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62: 870–4
   PubMed Web of Science ®Google Scholar
• Lopez‐Hoyos M., Ruiz de Alegria C., Blanco R., Crespo J., Peña M., Rodriguez‐Valverde V., et al. Clinical utility of anti‐CCP antibodies in the differential diagnosis of elderly‐onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004; 43: 655–7
   PubMed Web of Science ®Google Scholar
• Nielen M. M., van der Horst A. R., van Schaardenburg D., van der Horst‐Bruinsma I. E., van de Stadt R. J., Aarden L., et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005; 64: 1199–204
   PubMed Web of Science ®Google Scholar
• Pinheiro Q. C., Scheiberg M. A., Aparecida D. Anti‐cyclic citrullinated peptide antibodies in advanced RA. Ann Intern Med 2003; 139: 234–5
   PubMedGoogle Scholar
• Suzuki K., Sawada T., Murakami A., Matsui T., Tohma S., Nakazono K., et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 197–204
   PubMed Web of Science ®Google Scholar
• Vallbracht I., Rieber J., Oppermann M., Forger F., Siebert U., Helmke K. Diagnostic and clinical value of anti‐cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1079–84
   PubMed Web of Science ®Google Scholar
• Attia H. M., Gatee O. B., George S., Masri M. M. Rheumatoid arthritis in a population sample in the Gulf: clinical observations. Clin Rheumatol 1993; 12: 506–10
   PubMedGoogle Scholar
• Aho K., Palosuo T., Raunio V., Tuomi T. The timing of rheumatoid factor seroconversions. Arthritis Rheum 1987; 30: 719–20
   PubMedGoogle Scholar
• Du H., Masuko‐Hongo K., Nakamura H., Xiang Y., Bao C. D., Wang X. D., et al. The prevalence of autoantibodies against cartilage intermediate layer protein, YKL‐39, osteopontin, and cyclic citrullinated peptide in patients with early‐stage knee osteoarthritis: evidence of a variety of autoimmune processes. Rheumatol Int 2005; 26: 35–41
   PubMed Web of Science ®Google Scholar
• Mikuls T. R., Holers V. M., Parrish L., Kuhn K. A., Conn D. L., Gilkeson G., et al. Anti‐cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 3057–9
   PubMedGoogle Scholar
• Hall H. A., Lally E. V., Kadmon D. Prevalence of anti‐citrulline antibodies and rheumatoid factor in systemic sclerosis and systemic lupus erythematosus. Ann Rheum Dis 2005; 64((Suppl 3))907
   Google Scholar
• Korendowych E., Owen P., Ravindran J., Carmichael C., McHugh N. The clinical and genetic associations of anti‐cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 1056–60
   PubMed Web of Science ®Google Scholar
• Bogliolo L., Alpini C., Caporali R., Scirè C. A., Moratti R., Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32: 511–15
   PubMed Web of Science ®Google Scholar
• Nell V. P., Machold K. P., Stamm T. A., Eberl G., Heinzl H., Uffmann M., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1731–6
   PubMed Web of Science ®Google Scholar
• Mikuls T. R., O'Dell J. R., Stoner J. A., Parrish L. A., Arend W. P., Norris J. M., et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti‐cyclic citrullinated peptide antibody. Arthritis Rheum 2004; 50: 3776–82
   PubMed Web of Science ®Google Scholar
• Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti‐CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63: 1085–9
   PubMed Web of Science ®Google Scholar
• van Gaalen F. A., Linn‐Rasker S. P., van Venrooij W. J., de Jong B. A., Breedveld F. C., Verweij C. L., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709–15
   PubMed Web of Science ®Google Scholar
• Meyer O., Nicaise‐Roland P., Santos M. D., Labarre C., Dougados M., Goupille P., et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted five‐year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006; 8: R40
   PubMed Web of Science ®Google Scholar
• Samanci N., Ozdem S., Akbas H., Mutlu D., Gultekin M., Arman M., et al. Diagnostic value and clinical significance of anti‐CCP in patients with advanced rheumatoid arthritis. J Natl Med Assoc 2005; 97: 1120–6
   PubMedGoogle Scholar
• Symmons D. P. Classification criteria for rheumatoid arthritis: time to abandon rheumatoid factor?. Rheumatology 2007; 725–6
   PubMedGoogle Scholar